Royalty Pharma $2 billion senior notes offering
We advised Royalty Pharma on its investment-grade notes offering
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Strive Nasdaq listing and $450 million at-the-market offering
We advised Strive on its Nasdaq listing and offering
Enovix $360 million convertible senior notes and capped call transactions
The 4.75% convertible notes are due 2030
Elevance Health $3 billion senior notes offering
The investment-grade notes are due 2028, 2032, 2036 and 2055
Home Depot $2 billion notes offering
The investment-grade notes are due 2028, 2030 and 2035
Planet Labs PBC $460 million convertible senior notes offering
The 0.50% convertible senior notes are due 2030
Rowan $925 million project financing of three data centers
We advised the agent and arrangers on the facility
Gemini Space Station $450 million IPO
The shares are listed on the Nasdaq Global Select Market
VF $600 million sale of Dickies to Bluestar Alliance
We are advising VF on the transaction
Alnylam Pharmaceuticals $661.25 million convertible senior notes offering
The 0% convertible notes are due 2028